Connected With Latham
Episodes
Episode 107 – Drug Pricing and Market Access: "Think of It as a Loop" — Succeeding in an Evolving Policy Landscape
16 Dec 2025
Contributed by Lukas
The pharmaceutical industry has seen major legal and policy changes in recent years, from the Inflation Reduction Act to the Trump administration's ag...
Episode 106 – The FDA's New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway
15 Dec 2025
Contributed by Lukas
Recent FDA actions are reshaping key aspects of drug and biologic development, including the Commissioner's National Priority Voucher program, the "pl...
Episode 105 – Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits
24 Nov 2025
Contributed by Lukas
Government pricing assessments are an important tool to help pharmaceutical manufacturers review their government price reporting function, but they c...
Episode 104 – Drug Pricing and Market Access: Deep Dive on the FDA Commissioner's National Priority Voucher Program Awards
03 Nov 2025
Contributed by Lukas
The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to...
Episode 103 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
02 Oct 2025
Contributed by Lukas
Stakeholders from across the healthcare industry — from manufacturers and consultants to outside counsel and government officials — recently conve...
Episode 102 – EU Data Act: Spotlight on Switching Requirements for Data Processing Services
11 Sep 2025
Contributed by Lukas
In this episode of Connected With Latham, London partner Fiona Maclean, Paris partner Jean-Luc Juhan, and London counsel Alain Traill discuss signific...
Episode 101 – EU Data Act: Implications for Data Privacy and Cybersecurity
10 Sep 2025
Contributed by Lukas
In this episode of Connected With Latham, London partner Gail Crawford and Frankfurt partner Tim Wybitul discuss the EU Data Act, and what this means ...
Episode 100 – The Leeds Reforms: Implications for UK Financial Services
17 Jul 2025
Contributed by Lukas
In this episode of Connected with Latham, London partners Rob Moulton and Nicola Higgs discuss the UK government's plans for the financial services se...
Episode 99 – Drug Pricing: Takeaways from the Philadelphia Pricing and Contracting USA Conference
24 Jun 2025
Contributed by Lukas
Current developments, such as most favored nation (MFN) pricing, grabbed much of the spotlight when key industry stakeholders met in Philadelphia for ...
Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
06 Jun 2025
Contributed by Lukas
Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and ...
Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
02 May 2025
Contributed by Lukas
The "Lowering Drug Prices by Once Again Putting Americans First" Executive Order addresses various FDA matters, such as importation from Canada and ac...
Episode 96 – The Growth Rocketship: Shield AI's Takeoff Shows What's Possible in Defensetech
30 Apr 2025
Contributed by Lukas
Founded in 2015, Shield AI uses technology and intelligence systems to protect service members and civilians. The venture-backed unicorn's flagship au...
Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
12 Mar 2025
Contributed by Lukas
The initial months of the Trump administration have been marked by a flurry of executive orders and significant activity by the Department of Governme...
Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
25 Feb 2025
Contributed by Lukas
Stakeholders from across the healthcare and biopharmaceutical industry recently convened in San Francisco for the annual J.P. Morgan Healthcare Confer...
Episode 93 – EU's Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
16 Jan 2025
Contributed by Lukas
The deadline for the EU's Digital Operational Resilience Act (DORA) has arrived. This regulation applies to most financial entities operating in the E...
Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
06 Jan 2025
Contributed by Lukas
In this episode of Connected with Latham, the final of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services F...
Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
06 Jan 2025
Contributed by Lukas
In this episode of Connected with Latham, the second of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services ...
Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
06 Jan 2025
Contributed by Lukas
In this episode of Connected with Latham, the first of three episodes complementing Latham's "10 Key Focus Areas for UK-Regulated Financial Services F...
Episode 89 – The Growth Rocketship: How BridgeBio's Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What's Next?
30 Dec 2024
Contributed by Lukas
In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with BridgeBio'...
Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
16 Dec 2024
Contributed by Lukas
FDA enforcement activities range from administrative actions like conducting establishment inspections and issuing warning letters to judicial enforce...
Episode 87 – Drug Pricing: What's In the New CMS Medicaid Final Rule?
25 Nov 2024
Contributed by Lukas
The Centers for Medicare & Medicaid Services (CMS) recently published its final rule to implement the Medicaid Services Investment and Accountability ...
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
18 Oct 2024
Contributed by Lukas
Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this e...
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
19 Sep 2024
Contributed by Lukas
Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled t...
Episode 84 – Pro Bono: Shabir Kabiri's Remarkable Journey from Afghanistan to Asylum in the US
20 Aug 2024
Contributed by Lukas
In this episode of Connected with Latham, we explore the remarkable story of Shabir Kabiri, an Afghan refugee who secured asylum in the United States ...
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
19 Aug 2024
Contributed by Lukas
The US healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflati...
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
21 Jun 2024
Contributed by Lukas
Current developments grabbed much of the spotlight when key industry stakeholders met in New Orleans for the Pricing and Contracting USA Conference. I...
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
13 Jun 2024
Contributed by Lukas
The Centers for Medicare and Medicaid Services (CMS) recently updated its portal for Average Sales Price (ASP) reporting under Medicare Part B. Data c...
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
10 Jun 2024
Contributed by Lukas
As the energy tech sector continues to mature, venture capital offers an increasingly a viable path to growth as emerging energy tech companies seek t...
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
16 Apr 2024
Contributed by Lukas
Latham's recently released 2023 Pro Bono Annual Review highlights our public service initiatives around the world, including our ongoing relationship ...
Episode 78 – UK FinReg Focus Areas in 2024: ESG
08 Mar 2024
Contributed by Lukas
Following an array of ESG-focused regulation and escalating concerns of greenwashing risks in 2023, the year ahead looks to deliver significant indust...
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
05 Mar 2024
Contributed by Lukas
In 2023, the FCA brought more charges for fraud offences against individuals than any other year in the regulator's history, and secured several convi...
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
29 Feb 2024
Contributed by Lukas
The UK's announcement of the Edinburgh Reforms in 2022 made clear the government's intention to chart its own course in rulemaking for the UK financia...
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
23 Feb 2024
Contributed by Lukas
Two new Joint Executive Directors of Enforcement and Market Oversight appointed by the FCA in 2023 will settle into their roles over the year ahead. F...
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
19 Feb 2024
Contributed by Lukas
With the UK financial services regulators due to publish Policy Statements to their consultations on diversity and inclusion (D&I) this year, conduct ...
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
08 Feb 2024
Contributed by Lukas
The coming year looks poised to act as a pivotal junction for the UK financial services regulators in deciding how to approach the regulation of artif...
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
02 Feb 2024
Contributed by Lukas
Since the announcement of the Edinburgh Reforms in 2022, the UK government has made progress on an assortment of measures spanning financial services ...
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
01 Feb 2024
Contributed by Lukas
The pressure and uncertainty of 2023 will likely continue for drug manufacturers in 2024, with the election cycle bringing added scrutiny. At the fede...
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
31 Jan 2024
Contributed by Lukas
The UK's decision to scrap compulsory research unbundling, following the final recommendations of the Investment Research Review, marked one of the mo...
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
26 Jan 2024
Contributed by Lukas
As part of the FCA's continued focus on retail markets, updates to several key regimes are due to progress over the next year. In addition to further ...
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
25 Jan 2024
Contributed by Lukas
The National Institute of Standards and Technology (NIST) recently published a draft guidance framework for considering the exercise of march-in right...
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
23 Jan 2024
Contributed by Lukas
Cyberattacks targeting well-resourced businesses, especially those with institutional backing, financial support, and deep insurance coverage, have be...
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
19 Jan 2024
Contributed by Lukas
For the last three years, UK regulatory authorities have commissioned an array of reviews and consultations to address friction points in the UK's pri...
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
20 Dec 2023
Contributed by Lukas
Regulatory drivers and stakeholder demands have put environmental, social, and governance (ESG) considerations at the forefront of their agendas, with...
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
18 Dec 2023
Contributed by Lukas
As companies feel heightened pressure from stakeholders to adopt environmental, social, and governance (ESG) measures, greenwashing allegations contin...
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
14 Dec 2023
Contributed by Lukas
Regulators in the US, EU, and UK have increasingly scrutinized non-compete and no-poach clauses in employment agreements and M&A deals. The US Federal...
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
13 Dec 2023
Contributed by Lukas
Following a number of challenges to administrative enforcement on First Amendment grounds, the Food and Drug Administration (FDA) released a new draft...
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
07 Dec 2023
Contributed by Lukas
In November, the Department of Health and Human Services' Office of the Inspector General (OIG) issued new compliance program guidance that affirms OI...
Episode 60 – PE Views: Is the CMA's Focus on Roll-Up Transactions Here to Stay?
10 Nov 2023
Contributed by Lukas
The UK's Competition and Markets Authority (CMA) has increasingly asserted its jurisdiction to review private equity buy-and-build transactions, inclu...
Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
02 Nov 2023
Contributed by Lukas
On March 21, 2023, the US Supreme Court ruled for Miguel Luna Perez, a Latham pro bono client, in Perez v. Sturgis. Perez, who is deaf, was repeatedly...
Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
24 Oct 2023
Contributed by Lukas
As security interests have become increasingly important in Europe and globally, comprehensive investment control reviews are now an unavoidable eleme...
Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
20 Oct 2023
Contributed by Lukas
Not surprisingly, the Inflation Reduction Act (IRA) and its impact on the pharmaceutical industry was a key topic when manufacturers, government offic...
Episode 56 – M&A Views: Avoiding Buyer's Remorse in M&A Deals
27 Sep 2023
Contributed by Lukas
The buoyant market of 2021 and early 2022 resulted in compressed deal timelines and frenzied competition, causing many deals to be signed with fewer b...
Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?
21 Sep 2023
Contributed by Lukas
Startups in the insurtech sector have found increasing success in obtaining authorization from the Financial Conduct Authority (FCA). Yet the requirem...
Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act
15 Sep 2023
Contributed by Lukas
In a proposed rule issued earlier this summer, the Centers for Medicare & Medicaid Services (CMS) suggested expanding the scope of combining, or stack...
Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?
30 Aug 2023
Contributed by Lukas
As more energy and infrastructure companies commit to sustainability targets amidst the energy transition, sustainable finance options, such as green ...
Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?
21 Aug 2023
Contributed by Lukas
The policy conversation related to reimbursement rates for drugs has recently turned toward pricing for entire therapeutic classes, rather than assess...
Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem
31 Jul 2023
Contributed by Lukas
The Centers for Medicare & Medicaid Services (CMS) recently published its final guidance to implement the drug price negotiation provisions of the Inf...
Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?
14 Jul 2023
Contributed by Lukas
Consumer-facing companies face an increasingly complex UK regulatory landscape as multiple regulators place the spotlight on consumer rights and prote...
Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?
20 Jun 2023
Contributed by Lukas
Amid concerns of exaggerated or misleading sustainability claims, the UK Financial Conduct Authority's (FCA) proposal for new labelling and disclosure...
Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?
27 Apr 2023
Contributed by Lukas
Global M&A deal volumes have dipped at the start of Q1 2023, yet UK-bound M&A activity is expected to be one of the year's highlights as overseas buye...
Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity
17 Apr 2023
Contributed by Lukas
As interest rates soar to the highest rates in a decade, European real estate buyers and sellers are struggling to makes economic deals — transactio...
Episode 46 – PE Views: PE Must Strike the Right Balance With Unions
31 Mar 2023
Contributed by Lukas
Widespread economic pressure — including pay, inflation, and the ongoing cost of living crisis — has increased union visibility. As the number of ...
Episode 45 – Will Insurtech Reach New Heights in 2023?
08 Mar 2023
Contributed by Lukas
Insurtech has become a darling of both traditional players in the insurance market and disruptive fintech operations. The coming year looks to continu...
Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff
20 Jan 2023
Contributed by Lukas
Equity and co-investment opportunities have long served as tried and tested strategies for buyout firms seeking to incentivise management and align ke...
Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia's Digital Infrastructure Boom
01 Nov 2022
Contributed by Lukas
Digital infrastructure has become a basic component of all economies, and growth economies in particular. For many countries in Asia, digital infrastr...
Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?
11 Jul 2022
Contributed by Lukas
Not long ago, the prospect of significant PE investment in the cannabis industry would have been unthinkable for many. However, recent regulatory and ...
Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?
09 Jun 2022
Contributed by Lukas
Music deals, particularly the acquisition of rights to songs and recordings by popular music artists, remain attractive investments for PE. The contin...
Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of "Super Senior" RCFs in Leveraged Financings?
28 Apr 2022
Contributed by Lukas
Undrawn revolving credit facilities (RCFs) serve as essential parachutes to private equity. They are a backup in the event of mismatches in the workin...
Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022
15 Feb 2022
Contributed by Lukas
Now that the US Senate has confirmed Dr. Robert Califf as Commissioner of the US Food and Drug Administration, a position he held briefly in the Obama...
Episode 38 – PE Views: How are ESG Regulatory Reforms and Investor Focus Shaping the Market?
14 Feb 2022
Contributed by Lukas
Market sentiment and the increasing importance of environmental, social, and governance (ESG) to firms' competitiveness across the market, combined wi...
Episode 37 – Energy & Infrastructure: What's Behind The Wave of ESG Shareholder Activism?
10 Jan 2022
Contributed by Lukas
After years of garnering little attention, environmental, social, and governance (ESG) matters are now top-of-mind for institutional investors – and...
Episode 36 – Fintech Focus: The Year in Crypto – What Changed and What Comes Next in 2022?
04 Jan 2022
Contributed by Lukas
In 2021, the outlines of emerging crypto legal and regulatory regimes became steadily clearer. In the US, new regulators brought a fresh perspective a...
Episode 35 – PE Views: Is Gaming the Next Level for Private Equity?
14 Dec 2021
Contributed by Lukas
Global video game revenue in 2020 jumped by 20% to US$179.7 billion, making the sector larger than the film and North American sports industries combi...
Episode 34 – Fintech Focus: What's Next for Hong Kong and Singapore in 2022?
02 Dec 2021
Contributed by Lukas
The sixth annual Hong Kong and Singapore fintech events, both held in November 2021, revealed key new initiatives, regulatory developments, and market...
Episode 33 – PE Views: How is Creative Collateral Use Changing PE Finance Options?
19 Nov 2021
Contributed by Lukas
Raising fresh capital for portfolio companies in times of financial stress is always a delicate balancing act between attracting new lenders and maint...
Episode 32 – PE Views: Will UK IPOs with Dual Class Shares Surface New PE Opportunities?
10 Nov 2021
Contributed by Lukas
The UK has now seen several public listings with dual class share structures, including most the £5.4 billion IPO of The Hut Group, which had a "spec...
Episode 31 – PE Views: How is Growth Equity Connecting PE and VC?
03 Nov 2021
Contributed by Lukas
Emerging companies have historically been backed by venture capital funds, but as Europe's startup scene matures, involvement by more traditional priv...
Episode 30 – PE Views: Has the Pandemic Increased Whistleblowing Risks?
07 Oct 2021
Contributed by Lukas
As global businesses react to the pandemic and social movements, private equity firms should remain watchful for whistleblowing issues involving both ...
Episode 29 – Energy & Infrastructure: What's Driving the Oil & Gas Evolution in Europe?
01 Oct 2021
Contributed by Lukas
As commodity prices recover from pandemic lows, deal activity in the oil and gas sector is heating up across Europe. A number of factors are contribut...
Episode 28 – Energy & Infrastructure: What's the View From Inside the DOE Loan Programs Office?
11 Aug 2021
Contributed by Lukas
Jigar Shah is the recently appointed Executive Director of the Loan Programs Office at the US Department of Energy. He brings a robust resume to the p...
Episode 27 – Energy & Infrastructure: How Will EP4 Affect Projects in High-Income Countries?
07 Jul 2021
Contributed by Lukas
The Equator Principles set a minimum standard for lender due diligence and monitoring to support environmentally and socially responsible decision-mak...
Episode 26 – Energy & Infrastructure: Will the Market Sustain Its Interest in Sustainability-Linked Bonds?
25 May 2021
Contributed by Lukas
The interest in and availability of ESG-focused investments has exploded in recent years. Last year, the International Capital Markets Association pub...
Episode 25 – Fast Track to IPO: Why Are Series A Startups Snatching Topflight CFOs?
30 Apr 2021
Contributed by Lukas
Startups and scale-ups in Europe's tech and life sciences sectors have flourished dramatically over the past year, fueled by pandemic-induced demand a...
Episode 24 – Energy & Infrastructure: How Will the Biden Administration's Goals Affect the Energy Transition?
14 Apr 2021
Contributed by Lukas
The Biden Administration's climate goals are ambitious: A carbon free power sector by 2035. Net zero emissions by 2050. Targeting 40% of federal clima...
Episode 23 – Energy & Infrastructure: Renewables Driving Change in the Investment Landscape
01 Apr 2021
Contributed by Lukas
Macro market shifts as part of the energy transition are spurring investors, sponsors, and even traditional oil and gas producers to move in new direc...
Episode 22 – PE Views: Foreign Investment Controls – Are We Seeing a More Nuanced Approach to Private Equity?
11 Mar 2021
Contributed by Lukas
Governments' desire to control investments by businesses from purportedly hostile nations has led to more investments being stalled or blocked in rece...
Episode 21 – Healthcare Tech: How Are Licensing Agreements Bridging the Industry Divide?
03 Mar 2021
Contributed by Lukas
As the healthcare and technology sectors converge to create revolutionary new products and innovations, companies operating in very distinct regulator...
Episode 20 – Healthcare Tech: How Will the FDA Regulatory Framework Adapt to AI?
24 Feb 2021
Contributed by Lukas
Artificial intelligence (AI) is a burgeoning sector for investors and companies alike, but the unclear regulatory landscape for the use of AI in healt...
Episode 19 – Copyright & Brexit: How Will Article 15 of the EU Copyright Directive Affect Publishers and Platforms?
18 Feb 2021
Contributed by Lukas
Under Article 15 of the EU's Copyright Directive, "information society service providers" must compensate "publishers of press publications" for the u...
Episode 18 – Tech Trends: Has the Tide Turned for Transatlantic Data Transfers Post-Schrems II?
16 Feb 2021
Contributed by Lukas
After the EU's top court invalidated the Privacy Shield and cast doubt on the use of the model clauses in certain circumstances with consequences for ...
Episode 17 – Copyright & Brexit: Will the UK Copy the EU Directive or Develop Its Own Regime?
26 Jan 2021
Contributed by Lukas
The EU Copyright Directive, now implemented in Europe, did not "break the internet" as some feared, but has been controversial. With the longstop impl...
Episode 16 – Insolvency Reform: Spotting and Mitigating Future Risk in Supply Relationships
21 Jan 2021
Contributed by Lukas
With insolvency alone no longer valid grounds for severing most commercial contracts in the UK, how can suppliers and customers spot early warning sig...
Episode 15 – Healthcare Tech: What Legal Pitfalls Should Tech Companies Avoid As They Jump Into Healthcare?
13 Jan 2021
Contributed by Lukas
The US regulators have been particularly focused on new players in the health tech space and the novel regulatory issues their products present within...
Episode 14 – Fintech Focus: Crypto in the Crosshairs – What Regulatory Themes Characterized 2020?
07 Jan 2021
Contributed by Lukas
Throughout 2020, cryptocurrencies experienced incremental progress towards the mainstream as institutional investors and financial institutions made p...
Episode 13 – Fintech Focus: How Did Singapore Solidify Its Position as a Leading Fintech Hub in 2020?
18 Dec 2020
Contributed by Lukas
In 2020, Singapore solidified its position as a leading center of fintech innovation, as the country continued to advance legislation and regulations ...
Episode 12 – Fintech Focus: Payments During the Pandemic – What Key Legal and Regulatory Themes Emerged During 2020?
16 Dec 2020
Contributed by Lukas
2020 has been another year of growth for fintech and payments, as economies became increasingly cashless and alternative payment products and regulati...
Episode 11 – Restructuring in Asia: How Will Chinese Bond Defaults Resolve?
15 Dec 2020
Contributed by Lukas
With the second largest bond market in the world, China has weathered the economic downturn this year relatively well, without widespread credit dislo...
Episode 10 – PE Views: The Lipstick Effect — Why Are Beauty Deals Increasingly Attractive for Private Equity?
14 Dec 2020
Contributed by Lukas
Recent high-profile beauty M&A deals, coupled with economic turbulence, have brought renewed interest in the "lipstick effect" – when consumer deman...
Episode 9 – Tech Trends: CCPA and the Next Wave of Data Privacy Regimes
09 Dec 2020
Contributed by Lukas
Nearly a year after California's landmark Consumer Privacy Act (CCPA) went into effect, the reach and interlocking complexity of the world's data priv...
Episode 8 – Corporate Culture: How to Attain Sustainable Change
02 Dec 2020
Contributed by Lukas
Culture has become a point of focus for regulators and corporate stakeholders. The UK Financial Conduct Authority has taken a particular interest in c...